32 results about "Valvular disease" patented technology

A radially expandable endoprosthesis device and method of deployment with an at least two stage deployment capability. More particularly, the device pertains to an annularly expandable heart valve prosthesis which is adapted for the long-term treatment of valvular diseases in infants, children and adolescents. The device is constituted of a combination of superelastic alloys and bioresorabable materials which facilitates the devices to undergo multistage deployments at predetermined intervals while emplaced in the body vessels or lumens of patients.

Annuloplasty rings optimally sized to take into account more of the common degenerative valve pathologies. Each ring has a structural ring body with a shape that complies with predicted shapes of degenerative valvular diseases, such as fibroelastic deficiency (FED), Marfan's or Barlow's. The predicted shapes are obtained through careful echocardiographic and intraoperative measurements, and often differ for different annulus orifice sizes. For instance, in mitral rings the larger rings have larger minor axis and oblique axis dimensions relative to their major axis dimensions, and are more circular as opposed to D-shaped. The rings may also be three-dimensional and the relative heights around the rings may change for different sized rings. A mitral ring may have a higher anterior saddle relative to a posterior saddle, with the relative heights varying across the ring sizes. The ring may have varying flexibility around the ring periphery which also changes for different ring sizes. A bulge on the sewing cuff forms a step on the outflow side for ease of suturing, which may be indicated by a suture line.

A system is provided for treating valvular disease percutaneously though a ventricular apex of the heart. The system includes a needle for piercing through the ventricular apex of the heart and creating a hole whereby a catheter can be passed through the skin and the wall of the heart to gain access to the interior of the heart. Once percutaneous access to the heart is obtained, any of a variety of techniques can be utilized for annular and / or valvular therapy and / or repair through the catheter. A closure device is necessary for closing the puncture of the heart. Any of a variety of vascular closure devices can be modified to be utilized with the system to close the puncture of the ventricular apex of the heart.

Disclosed are single nucleotide polymorphisms (SNIps) associated with breast cancer, lung cancer, prostate cancer, non-insulin dependent diabetes, end stage renal disease due to non-insulin dependent diabetes, hypertension, end stage renal disease F due to hypertension, myocardial infarction, colon cancer, hypertension, atherosclerotic peripheral vascular disease due to hypertension, cerebrovascular accident due to hypertension, cataracts due to hypertension, cardiomyopathy with hypertension, myocardial infarction due to hypertension, non-insulin dependent diabetes mellitus, atherosclerotic peripheral vascular disease due to non-insulin dependent diabetes mellitus, cerebrovascular accident due to non-insulin dependent diabetes mellitus, ischemic cardiomyopathy, ischemic cardiomyopathy with non-insulin dependent diabetes mellitus, myocardial infarction due to non-insulin dependent diabetes mellitus, atrial fibrillations without valvular disease, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease. cholecystectomy, degenerative joint disease, end stage renal disease and frequent de-clots, end stage renal disease due to focal segmental glomerular sclerosis, end stage renal disease due to insulin dependent diabetes mellitus, or seizure disorder. Also disclosed are methods for using SNPs to determine susceptibility to these diseases; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs.

A set of annuloplasty rings progressively sized to take into account more of the common pathologies. The proportional shapes of each ring as the orifice size changes vary. For instance, the larger rings have larger minor axis dimensions relative to their major axis dimensions.

A system is provided for treating valvular disease percutaneously though a ventricular apex of the heart. The system includes a needle for piercing through the ventricular apex of the heart and creating a hole whereby a catheter can be passed through the skin and the wall of the heart to gain access to the interior of the heart. Once percutaneous access to the heart is obtained, any of a variety of techniques can be utilized for annular and / or valvular therapy and / or repair through, the catheter. A closure device is necessary for closing the puncture of the heart. Any of a variety of vascular closure devices can be modified to be utilized with the system to close the puncture of the ventricular apex of the heart.

Continuous wave Doppler images in a data base comprising cardiac echo studies are processed to separate Doppler frames. The frames are pre-processed to extract envelope curves and their corner shape features. Shape patterns in Doppler images from echo studies of patients with known cardiac (valvular) diseases are employed to infer the similarity in valvular disease labels for purposes of automated clinical decision support. Specifically, similarity in appearance of Doppler images from the same disease class is modeled as a constrained non-rigid translation transform of velocity envelopes embedded in these images. Shape similarity between two Doppler images is then judged by recovering the alignment transform using a variant of dynamic shape warping. Since different diseases appear as characteristic shape patterns in Doppler images, measuring the similarity in the shape pattern conveyed within the velocity region of two Doppler images can infer the similarity in their diagnosis labels.

An apparatus for treating or preventing a valvular disease comprises: a ultrasound probe located externally to a heart of patient, able to produce ultrasound waves focused inside the heart and suitable to generate, at a focal spot, a pressure sufficient to result in cavitation, an imaging device for mapping in real time a treatment region of a cardiac valve of the patient, the treatment region comprising at least one leaflet of the cardiac valve, a controller configured for driving the ultrasound probe to emit a sequence of focused ultrasound waves, the controller being further configured for steering the focused ultrasound waves so as to scan the entire treatment region to soften the tissues of the treatment region. A method for treating or preventing valvular disease, carried out using the apparatus is also provided.

A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide / phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

Continuous wave Doppler images in a data base comprising cardiac echo studies are processed to separate Doppler frames. The frames are pre-processed to extract envelope curves and their corner shape features. Shape patterns in Doppler images from echo studies of patients with known cardiac (valvular) diseases are employed to infer the similarity in valvular disease labels for purposes of automated clinical decision support. Specifically, similarity in appearance of Doppler images from the same disease class is modeled as a constrained non-rigid translation transform of velocity envelopes embedded in these images. Shape similarity between two Doppler images is then judged by recovering the alignment transform using a variant of dynamic shape warping. Since different diseases appear as characteristic shape patterns in Doppler images, measuring the similarity in the shape pattern conveyed within the velocity region of two Doppler images can infer the similarity in their diagnosis labels.

The present invention provides methods for preventing or treating a valvular stenosis or a valvular calcification in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide / phospholipid complex, wherein the peptide of the complex is an Apolipoprotein A-1 mimetic peptide. In one embodiment the Apolipoprotein A-1 mimetic peptide has the sequence set forth in SEQ ID NO: 1. In another embodiment the phospholipid of the complex is egg sphingomyelin and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine.

A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide / phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

Annuloplasty rings optimally sized to take into account more of the common degenerative valve pathologies. Each ring has a structural ring body with a shape that complies with predicted shapes of degenerative valvular diseases, such as Fibroelastic deficiency (FED), Marfan's or Barlow's. The predicted shapes are obtained through careful echocardiographic and intraoperative measurements, and often differ for different annulus orifice sizes. For instance, in mitral rings the larger rings have larger minor axis and oblique axis dimensions relative to their major axis dimensions, and are more circular as opposed to D-shaped. The rings may also be three-dimensional and the relative heights around the rings may change for different sized rings. A mitral ring may have a higher anterior saddle relative to a posterior saddle, with the relative heights varying across the ring sizes. The ring may have varying flexibility around the ring periphery which also changes for different ring sizes. A bulge on the sewing cuff forms a step on the outflow side for ease of suturing, which may be indicated by a suture line.

The invention relates to the technical field of in-vitro testing of medical instruments, in particular to a simulation cycle test system for ECMO (extracorporeal membrane oxygenation) and application of the simulation cycle test system. The invention provides the simulation cycle test system for ECMO. The simulation cycle test system comprises a pulmonary circulation simulation module, a flexible heart module, a systemic circulation simulation module, an ECMO detection module and a control detection module. The pulmonary circulation simulation module, the flexible heart module and the systemic circulation simulation module are used for simulating hemodynamic states of a human body under healthy and different pathological conditions. The control detection module is used for collecting data such as blood pressure, blood flow and oxyhemoglobin saturation and the like of each point in the test system, controlling the opening amplitude of each valve in the test system and simulating various cardiovascular and valvular diseases. A standardized ECMO testing environment is provided, a unified testing standard is provided for blood testing of ECMO and other interventional medical instruments, and meanwhile an effective basis is provided for ECMO clinical use risk assessment of patients with various valvular and cardiovascular diseases.

In various embodiments, provided herein are methods, devices and systems to optimize annular orientation of transcatheter valves and thereby facilitate transcatheter aortic valve replacement in the setting of challenging cardiovascular anatomy. These methods, devices and systems are used to treat patients with valvular diseases. To solve these problems, described herein is a Device to Optimize aNnUlar orientation of Transcathether valves (DONUT). DONUT can correct large differences between a native valve's anatomical dimensions and the external dimensions of a transcatheter valve stent frame.

The invention provides methods for diagnosing chronic valvular disease in an animal. The methods comprise obtaining a sample from the animal; analyzing the sample for an amount of a microRNA (miRNA) associated with chronic valvular disease; comparing the amount of the miRNA identified in the sample to a corresponding amount of the miRNA present in a sample from one or more comparable control animals that do not suffer from chronic valvular disease; and diagnosing the animal with chronic valvular disease if the amount of the miRNA found in the animal's sample is differentially expressed in the control animal's sample.

This invention relates to the production of dual models of Congenital Heart Defects and Hypertrophic Cardiomyopathy with the use of mice which are genetically modified by transgenic (gene-knockout) techniques. The present invention produces knockout mice that show multiple cardiovascular malformations which will serve as a model of cardiovascular diseases for the screening of potential drugs against ventricular remodeling, malignant arrhythmias, primary pulmonary hypertension, and degenerative valvular diseases, and congenital heart disease.

This document provides methods and materials related to assessing mammals for vascular disease. This document also provides methods and materials related to assessing mammals for valvular disease. For example, methods and materials for assessing mammals for vascular disease using elevated levels of endothelial progenitor cells expressing a bone-related polypeptide (e.g., an osteocalcin polypeptide) as markers are provided.

The invention relates to novel application of a medicine, and in particular relates to an adjuvant treatment effect of tofacitinib on senile degenerative valvular disease. A clinical trial research shows that while conventional treatment is carried out on a patient with the senile degenerative valvular disease, the tofacitinib can be given for adjuvant treatment; the tofacitinib can be used for remarkably treating lung extravasated blood and pleural effusion symptoms of the patient with the senile degenerative valvular disease; various arrhythmia including auricular fibrillation and the like, atrial hypertrophy and ventricular hypertrophy are effectively relieved; the recurrence rate of the disease can be reduced, and the life quality of the patient is improved.

In various embodiments, provided herein are methods, devices and systems to optimize annular orientation of transcatheter valves and thereby facilitate transcatheter aortic valve replacement in the setting of challenging cardiovascular anatomy. These methods, devices and systems are used to treat patients with valvular diseases. To solve these problems, described herein is a Device to Optimize aNnUlar orientation of Transcathether valves (DONUT). DONUT can correct large differences between a native valve's anatomical dimensions and the external dimensions of a transcatheter valve stent frame.

The invention belongs to the technical field of medical instruments, and particularly relates to the field of A61M25 / 04, in particular to a dual balloon capable of accurately positioning and expanding. The dual balloon comprises an inner balloon, an outer balloon and a cavity tube component, wherein the inner balloon and the outer balloon are both arranged to be of a closed cavity structure; the inner balloon is arranged in the cavity structure of the outer balloon; the inner balloon and the outer balloon are coaxially arranged; the material hardness of the outer balloon is greater than that of the inner balloon; the cavity tube component is arranged to be of a tube barrel type structure with the axial length; the cavity tube component extends into the cavity structures of the inner balloon and the outer balloon and penetrates through the inner balloon and the outer balloon; on the far end and the near end of the inner balloon, the inner balloon is respectively fixedly connected with the outer wall of the cavity tube component in a sealed mode; and on the far end and the near end of the outer balloon, the outer balloon is respectively fixedly connected with the outer wall of the cavity tube component in a sealed mode. The dual balloon is applied to the treatment process of narrow and calcified valvular diseases, and the balloon is prevented from sliding in an expansion process.

The present invention relates to the application of miRNA in the treatment of myocardial hypertrophy. Specifically, the miRNA is hsa-miR-15a-5p / hsa-miR-16-5p, and its nucleotide sequences are respectively as SEQ ID NO.1 and SEQ ID NO.1. Shown in ID NO.2. The cardiac hypertrophy refers to a pathophysiological process mainly characterized by thickening of the ventricular muscle and narrowing of the chamber caused by the overload of the heart caused by heredity, hypertension, myocardial infarction, valvular disease and the like. The present invention also relates to the application of the complex loaded with hsa-miR-15a-5p / hsa-miR-16-5p in the preparation of medicine for treating myocardial hypertrophy, the complex being CHO-PGEA-nucleic acid complex.

Annuloplasty rings optimally sized to take into account more of the common degenerative valve pathologies. Each ring has a structural ring body with a shape that complies with predicted shapes of degenerative valvular diseases, such as Fibroelastic deficiency (FED), Marfan's or Barlow's. The predicted shapes are obtained through careful echocardiographic and intraoperative measurements, and often differ for different annulus orifice sizes. For instance, in mitral rings the larger rings have larger minor axis and oblique axis dimensions relative to their major axis dimensions, and are more circular as opposed to D-shaped. The rings may also be three-dimensional and the relative heights around the rings may change for different sized rings. A mitral ring may have a higher anterior saddle relative to a posterior saddle, with the relative heights varying across the ring sizes. The ring may have varying flexibility around the ring periphery which also changes for different ring sizes. A bulge on the sewing cuff forms a step on the outflow side for ease of suturing, which may be indicated by a suture line.

An animal selected for lacking heparan sulfate 3-O-sulfotransferase-1 activity is provided. This animal exhibits characteristics associated with myxomatous valvular disease and is useful for identifying agents which prevent, delay or treat myxomatous valvular disease. Methods of diagnosing myxomatous valvular disease are also provided.

The invention relates to novel application of a medicine, and in particular relates to an adjuvant treatment effect of tofacitinib on senile degenerative valvular disease. A clinical trial research shows that while conventional treatment is carried out on a patient with the senile degenerative valvular disease, the tofacitinib can be given for adjuvant treatment; the tofacitinib can be used for remarkably treating lung extravasated blood and pleural effusion symptoms of the patient with the senile degenerative valvular disease; various arrhythmia including auricular fibrillation and the like, atrial hypertrophy and ventricular hypertrophy are effectively relieved; the recurrence rate of the disease can be reduced, and the life quality of the patient is improved.

The invention discloses an identity recognition system and method based on cardiac function dynamic monitoring and analysis. The identity recognition includes database establishment, feature spectrumextraction, feature query, comparison and an identity discrimination device and method. The identity recognition technology is applied to a portable smart heart patch system which is worn in the center of the human chest in the form of a wearable device, in-vitro monitoring is conducted on cardiac mechanical vibration, vibration information of the heart is obtained non-invasively in real time, bycombining digital processing, machine learning and artificial intelligence technology pattern recognition and intelligent diagnosis, cardiac physical structures and abnormal beating rhythms such as valvular disease, abnormal motion of the heart wall, cardiac ejection fraction change and arrhythmia are found in the early stage. By combining an early warning report system, the purposes of early warning and timely medical care of the heart disease are achieved. Early warning monitoring of severe arrhythmias, angina pectoris and acute myocardial infarction is achieved, and by contrasting rehabilitation monitoring after surgery, monitoring for home-based care people and sports people is achieved.

An animal selected for lacking heparan sulfate 3-O-sulfotransferase-1 activity is provided. This animal exhibits characteristics associated with myxomatous valvular disease and is useful for identifying agents which prevent, delay or treat myxomatous valvular disease. Methods of diagnosing myxomatous valvular disease are also provided.

An apparatus for treating or preventing a valvular disease comprises: a ultrasound probe located externally to a heart of patient, able to produce ultrasound waves focused inside the heart and suitable to generate, at a focal spot, a pressure sufficient to result in cavitation, an imaging device for mapping in real time a treatment region of a cardiac valve of the patient, the treatment region comprising at least one leaflet of the cardiac valve, a controller configured for driving the ultrasound probe to emit a sequence of focused ultrasound waves, the controller being further configured for steering the focused ultrasound waves so as to scan the entire treatment region to soften the tissues of the treatment region. A method for treating or preventing valvular disease, carried out using the apparatus is also provided.

This invention relates to the production of dual models of Congenital Heart Defects and Hypertrophic Cardiomyopathy with the use of mice which are genetically modified by transgenic (gene-knockout) techniques. The present invention produces knockout mice that show multiple cardiovascular malformations which will serve as a model of cardiovascular diseases for the screening of potential drugs against ventricular remodeling, malignant arrhythmias, primary pulmonary hypertension, and degenerative valvular diseases, and congenital heart disease.